The molecular phenotype of 6-week protocol biopsies from human renal allografts: Reflections of prior injury but not future course

American Journal of Transplantation

Volumn 11, Issue 4, 2011, Pages 708-718

  Mengel, M ^a,b   Chang, J ^b   Kayser, D ^b,c   Gwinner, W ^c   Schwarz, A ^c   Einecke, G ^c   Broecker, V ^c   Famulski, K ^a,b   De Freitas, D G ^b   Guembes Hidalgo, L ^a,b   Sis, B ^a,b   Haller, H ^c   Halloran, P F ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Graft rejection; kidney injury; kidney transplants; microarrays; protocol biopsies

Indexed keywords

GAMMA INTERFERON;

ADULT; AGED; ARTICLE; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MICROCIRCULATION; PARENCHYMA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; STROMA; T LYMPHOCYTE;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; DELAYED GRAFT FUNCTION; FEMALE; GENE EXPRESSION PROFILING; GRAFT REJECTION; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; T-LYMPHOCYTES; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79953247992     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03339.x     Document Type: Article

References (45)

1. Solez K, Axelsen RA, Benediktsson H, et al,. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422. (Pubitemid 23228698)
2. Solez K, Vincenti F, Filo RS,. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplant 1998; 66: 1736-1740. (Pubitemid 29035001)
3. Mengel M, Bogers J, Bosmans JL, et al,. Incidence of C4d stain in protocol biopsies from renal allografts: Results from a multicenter trial. Am J Transplant 2005; 5: 1050-1056. (Pubitemid 40571253)
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333. (Pubitemid 37509740)
5. Rush D, Nickerson P, Gough J, et al,. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 2129-2134. (Pubitemid 28482163)
6. Schwarz A, Mengel M, Gwinner W, et al,. Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005; 67: 341-348. (Pubitemid 40019257)
7. Seron D, Moreso F, Bover J, et al,. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310-316. (Pubitemid 27064552)
8. Veronese FV, Manfro RC, Roman FR, et al,. Reproducibility of the Banff classification in subclinical kidney transplant rejection. Clin Transplant 2005; 19: 518-521. (Pubitemid 40990663)
9. Rush D, Arlen D, Boucher A, et al,. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007; 7: 2538-2545. (Pubitemid 47561621)
10. Famulski KS, Einecke G, Sis B, et al,. Defining the canonical form of T Cell-mediated rejection in human kidney transplants. Am J Transplant 2010; 10: 810-820.
11. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
12. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplant 2004; 78: 242-249.
13. Nankivell BJ, Chapman JR,. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 2006-2012. (Pubitemid 44199535)
14. Seron D, Moreso F,. Protocol biopsies in renal transplantation: Prognostic value of structural monitoring. Kidney Int 2007; 72: 690-697. (Pubitemid 47373786)
15. Thaunat O, Legendre C, Morelon E, Kreis H, Mamzer-Bruneel MF,. To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplant 2007; 84: 671-676. (Pubitemid 47480648)
16. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
17. El Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
18. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure 1. Transplant 2010; 90: 68-74.
19. Halloran PF, de Freitas DG, Einecke G, et al,. An integrated view of molecular changes, histopathology, and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
20. Mengel M, Gwinner W, Schwarz A, et al,. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7: 356-365. (Pubitemid 46096328)
21. Merion RM., 2009 SRTR Report on the State of Transplantation. Am J Transplant 2010; 10 (4 Pt 2): 959-960.
22. Bunnag S, Einecke G, Reeve J, et al,. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009; 20: 1149-1160.
23. Mueller TF, Einecke G, Reeve J, et al,. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7: 2712-2722. (Pubitemid 350045779)
24. Reeve J, Einecke G, Mengel M, et al,. Diagnosing rejection in renal transplants: A comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9: 1802-1810.
25. Sis B, Jhangri G, Bunnag S, Allanach K, Kaplan B, Halloran PF,. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
26. Schwarz A, Mengel M, Gwinner W, et al,. Protocol biopsy program after renal transplantation: Structure and first results. Transplant. Proc. 2002; 34: 2238-2239. (Pubitemid 35299729)
27. Sis B, Mengel M, Haas M, et al,. Banff '09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups. Am J Transplant 2009; 10: 464-471.
28. Einecke G, Melk A, Ramassar V, et al,. Expression of CTL associated transcripts precedes the development of tubulitis in T cell mediated kidney graft rejection. Am J Transplant 2005; 5: 1827-1836. (Pubitemid 41039855)
29. Einecke G, Broderick G, Sis B, Halloran PF,. Early loss of renal transcripts in kidney allografts: Relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant 2007; 7: 1121-1130. (Pubitemid 46643125)
30. Famulski KS, Einecke G, Reeve J, et al,. Changes in the transcriptome in allograft rejection: IFN-γ induced transcripts in mouse kidney allografts. Am J Transplant 2006; 6: 1342-1354. (Pubitemid 44030317)
31. Famulski KS, Broderick G, Hay K, et al,. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007; 7: 2483-2495. (Pubitemid 47561622)
32. Hidalgo LG, Einecke G, Allanach K, et al,. The transcriptome of human cytotoxic T cells: Measuring the burden of CTL-associated transcripts in human kidney transplants. Am J Transplant 2008; 8: 637-646. (Pubitemid 351287556)
33. Mengel M, Sis B, Kim D, et al,. The molecular phenotype of heart transplant biopsies: Relationship to histopathological and clinical variables. Am J Transplant 2010; 10: 2105-2115.
34. Famulski K, Sis B, Billesberger L, Halloran P,. Interferon-γ and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: A shift in the TH1-TH2 paradigm. Am J Transplant 2008; 8: 547-556. (Pubitemid 351287549)
35. Famulski KS, Kayser D, Einecke G, et al,. Alternative macrophage activation is associated with parenchymal deterioration in T cell mediated rejection of mouse kidneys. Am J Transplant 2010; 10: 490-497.
36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
37. Halloran PF, de Freitas DG, Einecke G, et al,. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10: 2215-2222.
38. Park W, Griffin M, Grande JP, Cosio F, Stegall M,. Molecular evidence of injury and inflammation in normal and fibrotic renal allografts one year posttransplant. Transplant 2007; 83: 1466-1476. (Pubitemid 46934070)
39. Scherer A, Krause A, Walker JR, Korn A, Niese D, Raulf F,. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplant 2003; 75: 1323-1330. (Pubitemid 36513042)
40. Scherer A, Gwinner W, Mengel M, et al,. Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6 months. Nephrol Dial Transplant 2009; 24: 2567-2575.
41. Vitalone MJ, O'Connell PJ, Jimenez-Vera E, et al,. Epithelial-to- mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol 2008; 19: 1571-1583.
42. Vitalone MJ, O'Connell PJ, Wavamunno M, Fung CL, Chapman JR, Nankivell BJ,. Transcriptome changes of chronic tubulointerstitial damage in early kidney transplantation. Transplant 2010; 89: 537-547.
43. Halloran PF,. T cell-mediated rejection of kidney transplants: A personal viewpoint. [Review][58 refs]. Am J Transplant 2010; 10: 1126-1134.
44. Mueller TF, Reeve J, Jhangri GS, et al,. The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function. Am J Transplant 2008; 8: 78-85.
45. Loupy A, Suberbielle-Boissel C, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.